A new anti hepatitis drug of Guizhou bailing, tefentai, will be put into clinical trial soon

Recently, the latest status of Guizhou bailing's heavyweight drug, tefentai (original Y101), was changed to "approved - to be certified" This means that the company's class 1.1 innovative drug, tefentai, has made a significant R & D breakthrough in the treatment of hepatitis B, has been recognized by the national drug regulatory department, and has officially entered the clinical trial stage Generally, it takes 1-2 weeks from the announcement of "approval completed - Certificate to be prepared" to "approval issued", and then it will be issued to the enterprise from the provincial department That is to say, if there is no accident, Guizhou bailing will receive the clinical approval from tifentai within 1 month 　　 Tifentai is a new type of hepatitis B treatment chemical synthesized on the principle of the medicine of the extract of horseshoe gold, a Miao medicine It was developed by Guizhou bailing in cooperation with the Key Laboratory of natural product chemistry, Chinese Academy of Sciences, Tianjin Pharmaceutical Research Institute and 302 Hospital of the people's Liberation Army It has a history of more than 10 years from its establishment to its research and development It has repeatedly won the national key new drug project and the local medicine of Guizhou Province Special support funds China is a big country of hepatitis B It is conservatively estimated that the market of hepatitis B drugs will exceed 300 billion yuan, with an annual increase of 10 billion yuan The prospect of hepatitis B drugs market is broad According to the R & D personnel, the pharmaceutical, pharmacodynamics, safety, drug metabolism and other aspects of tefentai have made good progress After the R & D is completed and put on the market, the price will be lower than that of imported drugs, which is expected to achieve the strategic goal of replacing imported hepatitis B drugs